SB-366791

C₁₆H₁₄NO₂Cl

287.74

MFCD01033818

24278690

NA.77

SB-366791 has been used as a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist:

• to infer the in vitro and in vivo pharmacology of (E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)acrylamide (AMG 9810)
• to study its effects on sodium hydrogen sulfide (NaHS) or capsaicin-induced contractile activity
• to study the inhibitory potency of phoneutria toxin (PnTx3-5) (native and recombinant) on various responses mediated by transient receptor potential cation channel subfamily V member 1 (TRPV1)

SB-366791 might exhibit analgesic properties on bone cancer-related pain behavior.
Vanilloid receptor-1 (TRPV1) antagonist.

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

≥98% (HPLC)

powder

white to beige

DMSO: 5 mg/mL, clear

GlaxoSmithKline

COc1cccc(NC(=O)\C=C\c2ccc(Cl)cc2)c1

1S/C16H14ClNO2/c1-20-15-4-2-3-14(11-15)18-16(19)10-7-12-5-8-13(17)9-6-12/h2-11H,1H3,(H,18,19)/b10-7+

RYAMDQKWNKKFHD-JXMROGBWSA-N

human ... TRPV1(7442)

5 mg in glass bottle

13 - Non Combustible Solids

WGK 3

Eyeshields, Gloves, type N95 (US)